HIF2α is a key target for ccRCC [2–5], and the FDA recently approved a HIF2α inhibitor, Belzutifan, which has an overall response rate of 49% in Von Hippel-Lindau (VHL) mutant ccRCC [6]. Here, VHL is linked to nonpapillary renal cell carcinoma.